Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
11.85
-0.51 (-4.13%)
Mar 2, 2026, 3:04 PM CST
-3.42%
Market Cap 19.77B
Revenue (ttm) 2.40B
Net Income (ttm) 49.24M
Shares Out 1.60B
EPS (ttm) 0.03
PE Ratio 401.42
Forward PE 76.06
Dividend 0.03 (0.24%)
Ex-Dividend Date Jan 9, 2026
Volume 40,294,586
Average Volume 58,839,757
Open 12.18
Previous Close 12.36
Day's Range 11.81 - 12.24
52-Week Range 9.70 - 14.65
Beta 0.57
RSI 50.76
Earnings Date Mar 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The... [Read more]

Sector Healthcare
Founded 2001
Employees 2,388
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.

Financial Statements

News

There is no news available yet.